Fundamental Analysis of TRINITY BIOTECH PLC-SPON ADR(NASDAQ:TRIB) stock

Fundamental Rating

TRIB gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 188 industry peers in the Health Care Equipment & Supplies industry. TRIB has a bad profitability rating. Also its financial health evaluation is rather negative. TRIB is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year TRIB has reported negative net income.

In the past year TRIB has reported a negative cash flow from operations.

TRIB had negative earnings in 4 of the past 5 years.

In multiple years TRIB reported negative operating cash flow during the last 5 years.

1.2 Ratios

The Return On Assets of TRIB (-23.63%) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-23.63%
ROE	N/A
ROIC	N/A

ROA(3y)-28.07%

ROA(5y)-22.23%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

TRIB has a worse Gross Margin (34.27%) than 70.59% of its industry peers.

TRIB's Gross Margin has declined in the last couple of years.

The Profit Margin and Operating Margin are not available for TRIB so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	34.28%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-10.44%

GM growth 5Y-4.34%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

TRIB does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, TRIB has less shares outstanding

TRIB has more shares outstanding than it did 5 years ago.

Compared to 1 year ago, TRIB has a worse debt to assets ratio.

2.2 Solvency

TRIB has an Altman-Z score of -0.43. This is a bad value and indicates that TRIB is not financially healthy and even has some risk of bankruptcy.

TRIB's Altman-Z score of -0.43 is in line compared to the rest of the industry. TRIB outperforms 42.25% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-0.43

ROIC/WACCN/A

WACC9.42%

2.3 Liquidity

A Current Ratio of 1.78 indicates that TRIB should not have too much problems paying its short term obligations.

TRIB has a worse Current ratio (1.78) than 72.73% of its industry peers.

TRIB has a Quick Ratio of 1.78. This is a bad value and indicates that TRIB is not financially healthy enough and could expect problems in meeting its short term obligations.

The Quick ratio of TRIB (0.89) is worse than 84.49% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.78
Quick Ratio	0.89

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

TRIB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 35.39%, which is quite impressive.

Looking at the last year, TRIB shows a decrease in Revenue. The Revenue has decreased by -2.50% in the last year.

Measured over the past years, TRIB shows a very negative growth in Revenue. The Revenue has been decreasing by -10.15% on average per year.

EPS 1Y (TTM)35.39%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%4.8%

Revenue 1Y (TTM)-2.5%

Revenue growth 3Y-17.71%

Revenue growth 5Y-10.15%

Sales Q2Q%13.99%

3.2 Future

TRIB is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -32.13% yearly.

TRIB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.13% yearly.

EPS Next Y-257.63%

EPS Next 2Y-32.13%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year12.43%

Revenue Next 2Y11.13%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

TRIB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year TRIB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as TRIB's earnings are expected to decrease with -32.13% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-32.13%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

TRIB does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

TRINITY BIOTECH PLC-SPON ADR

NASDAQ:TRIB (11/22/2024, 8:09:23 PM)

After market: 1.24 +0.02 (+1.64%)

1.22

-0.08 (-6.15%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap11.55M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-23.63%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	34.28%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.62

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	1.78
Quick Ratio	0.89
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)35.39%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y-257.63%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-2.5%

Revenue growth 3Y-17.71%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

TRINITY BIOTECH PLC-SPON ADR (TRIB)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens